PL2806028T3 - Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych - Google Patents

Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych

Info

Publication number
PL2806028T3
PL2806028T3 PL14154643T PL14154643T PL2806028T3 PL 2806028 T3 PL2806028 T3 PL 2806028T3 PL 14154643 T PL14154643 T PL 14154643T PL 14154643 T PL14154643 T PL 14154643T PL 2806028 T3 PL2806028 T3 PL 2806028T3
Authority
PL
Poland
Prior art keywords
recruitment
migration
compounds
reducing
methods
Prior art date
Application number
PL14154643T
Other languages
English (en)
Polish (pl)
Inventor
Charlotte Admyre
Lars-Göran Axelsson
Stein Oliver Von
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of PL2806028T3 publication Critical patent/PL2806028T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL14154643T 2008-11-04 2009-10-28 Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych PL2806028T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11128408P 2008-11-04 2008-11-04
SE0802338 2008-11-04
EP14154643.2A EP2806028B1 (en) 2008-11-04 2009-10-28 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells

Publications (1)

Publication Number Publication Date
PL2806028T3 true PL2806028T3 (pl) 2017-11-30

Family

ID=42153087

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14154643T PL2806028T3 (pl) 2008-11-04 2009-10-28 Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych

Country Status (11)

Country Link
US (2) US8877724B2 (cg-RX-API-DMAC7.html)
EP (2) EP2806028B1 (cg-RX-API-DMAC7.html)
JP (1) JP5749651B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009311748B2 (cg-RX-API-DMAC7.html)
CA (1) CA2778938C (cg-RX-API-DMAC7.html)
DK (2) DK2806028T3 (cg-RX-API-DMAC7.html)
ES (2) ES2464731T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171360T1 (cg-RX-API-DMAC7.html)
LT (1) LT2806028T (cg-RX-API-DMAC7.html)
PL (1) PL2806028T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010053430A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350283T3 (en) * 2008-11-04 2016-02-01 Index Pharmaceuticals Ab RELATIONS AND PROCEDURES FOR THE TREATMENT OF INFLAMMATORY DISEASES IN THE CENTRAL NERVOUS SYSTEM
WO2012084996A2 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
EP2468867A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Methods for identifying biologically active oligonucleotides capable of modulating the immune system
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
PT1163204E (pt) 1999-03-18 2005-11-30 Brigham & Womens Hospital Compostos a base de lipoxina e sua utilizacao
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
JP2006527741A (ja) * 2003-06-19 2006-12-07 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ 細胞遊走の阻害剤
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
EP1940419A2 (en) 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
WO2007030580A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
DK2573176T3 (en) 2007-05-04 2016-08-01 Index Pharmaceuticals Ab Tumor growth retardant compounds and methods of use thereof
DK2350283T3 (en) 2008-11-04 2016-02-01 Index Pharmaceuticals Ab RELATIONS AND PROCEDURES FOR THE TREATMENT OF INFLAMMATORY DISEASES IN THE CENTRAL NERVOUS SYSTEM
US20110280934A1 (en) 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens

Also Published As

Publication number Publication date
US20150099799A1 (en) 2015-04-09
WO2010053430A1 (en) 2010-05-14
JP2012507307A (ja) 2012-03-29
US10046006B2 (en) 2018-08-14
EP2342341B1 (en) 2014-03-05
DK2342341T3 (da) 2014-05-12
US8877724B2 (en) 2014-11-04
HRP20171360T1 (hr) 2017-11-03
ES2464731T3 (es) 2014-06-03
AU2009311748A1 (en) 2010-05-14
LT2806028T (lt) 2017-12-11
CA2778938C (en) 2019-07-02
US20110301225A1 (en) 2011-12-08
CA2778938A1 (en) 2010-05-14
AU2009311748B2 (en) 2014-08-21
JP5749651B2 (ja) 2015-07-15
EP2342341A1 (en) 2011-07-13
EP2806028A3 (en) 2015-03-11
DK2806028T3 (en) 2017-10-09
ES2641751T3 (es) 2017-11-13
EP2342341A4 (en) 2013-01-09
EP2806028B1 (en) 2017-07-12
EP2806028A2 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
HRP20171360T1 (hr) Spojevi i postupci smanjivanja novačenja i/ili seljenja polimorfonuklearnih stanica
IL252119A0 (en) Improved composition of cells and methods for its preparation
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
EP2285217A4 (en) CONNECTIONS TO IMPROVE LEARNING AND MEMORY
ZA201006687B (en) Oxymethylene aryl compounds and uses thereof
IL209740A0 (en) Methods for the production of ips cells using non-viral approach
EP2281696A4 (en) Decorative structure for article surface and processing method for it
EP2129369A4 (en) TREATMENT OF ADHD
GB0823074D0 (en) Design and method of assembly of cdi cells
IL247136B (en) Compounds for reducing uric acid and their uses
EP2464652A4 (en) HAFNIUM AND ZIRCONIUM-CONTAINING PRECEDENTS AND METHOD OF USE THEREOF
EP2069477A4 (en) CHEMICAL REPULSION OF CELLS
EP2318508A4 (en) DETERMINATION OF RNA INTEGRITY
IL217966A0 (en) Hsl inhibitors useful in the treatment of diabetes
IL211567A0 (en) Use of stem cells to prevent neuronal dieback
ZA201000381B (en) Use of yeast cell walls for treating and/or preventing hyper-insulinemia
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
PL2446276T3 (pl) Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu
IL205452A0 (en) Methods of treating scleroderma
EP2121042A4 (en) COMPOUNDS AND METHOD FOR THE DETECTION OF CELLS
GB0817240D0 (en) Modified bacterial cell
PL2285780T3 (pl) Sposoby i związki do wytwarzania normorfinanów
GB0805670D0 (en) Increasing the plasticity of stem cells
IL199671A0 (en) Compounds and methods for detection of cells
IL244553B (en) Altered placental cells